hexamethonium has been researched along with Thyroid Neoplasms in 1 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, Y | 1 |
| Dong, S | 1 |
| Liu, J | 1 |
| Zhang, L | 1 |
| Zhang, J | 1 |
| Zhou, H | 1 |
| Dong, W | 1 |
1 other study available for hexamethonium and Thyroid Neoplasms
| Article | Year |
|---|---|
Identification of Potential Biomarkers for Thyroid Cancer Using Bioinformatics Strategy: A Study Based on GEO Datasets.
Topics: Androstenes; Biomarkers, Tumor; Clofazimine; Computational Biology; Databases, Genetic; Exosomes; Ex | 2020 |